Photo generated from meetings.asco.org
Jun 3, 2024, 13:08
Gilberto Lopes: In phase 3 EVOKE-01 study improvement of OS was noted in patients without response to prior IO
Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared a post on X:
“LBA out: Phase 3 EVOKE-01 study. Sacituzumab vs Docetaxel… and… no better! Underwhelming results. One subgroup to note ‘Clinically meaningful improvement of OS was noted in patients without response to prior IO’. 383 patients OS 8.3 vs 11.8 for these patients HR 0.75 (0.58–0.97).”
Read further
Source: Gilberto Lopes/X